key: cord-0992784-w3fbuyw7
authors: King, Paul T.
title: Late presentation of organising pneumonia in COVID‐19
date: 2021-06-21
journal: Intern Med J
DOI: 10.1111/imj.15342
sha: 4d013a35b2f5d3a3366eda6eab0ead4eb418b5f5
doc_id: 992784
cord_uid: w3fbuyw7

nan

A 58-year-old man developed coryzal symptoms, temperature and systemic malaise and had a positive swab for COVID-19. He presented to the hospital and was hypoxic; a chest X-ray demonstrated a widespread infiltrate. He was admitted to the intensive care unit (ICU) and was commenced on dexamethasone at 6 mg daily and remdesivir with high-flow oxygen. He was initially markedly hypoxic with a nadir saturation of 81% recorded, while on 50% oxygen. His hypoxia improved in the ICU and after 4 days he was transferred to the standard ward with supplemental oxygen. After 8 days, his dexamethasone was ceased and he was discharged home.

He was subsequently reviewed 2 months after discharge and he was still complaining of significant symptoms of dyspnoea, cough and malaise. There were no other obvious features of long COVID-19. A computed tomography (CT) scan done after review demonstrated widespread ground-glass infiltrates (Fig. 1 ). Lung function testing demonstrated normal lung volumes with a forced expiratory volume in 1 s (FEV1) of 90% of predicted, a forced vital capacity (FVC) of 88% of predicted and a reduced lung diffusing capacity for carbon monoxide (DLCO) at 68% of predicted. The features were consistent with organising pneumonia (OP). He was treated with a moderate dose of 25 mg of prednisolone daily.

He remained on the same dose and was reviewed 2 months later. At that time, he felt that his symptoms had resolved and he had gone back to work. His lung function demonstrated a marked improvement with FEV1 of 107% predicted, FVC of 102% predicted and DLCO of 96% predicted. A repeat CT demonstrated significant improvement in the ground-glass infiltrates. He was prescribed a weaning dose of prednisolone.

A proportion of patients develop a variety of chronic symptoms beyond the initial acute illness; this has been designated as 'long COVID-19'. Respiratory manifestations are a prominent component of this syndrome, although the number of published studies is relatively limited. 1,2 OP is a relatively rare condition characterised by persistent respiratory symptoms, patchy ground-glass infiltrate on CT and specific pathological lesions, that may cause permanent lung damage if untreated. Reports have described OP occurring in patients first presenting to the hospital with COVID-19 3 and responding to prednisolone. 4 The patient in the current report is a little different than that described in the other studies in that he received the currently recommended therapy of dexamethasone and presented 2 months after discharge. The patient did not have a pathologic confirmation of OP, although the clinical and radiological features were consistent with this condition.

There are very limited guidelines available as to how long COVID-19 should be managed. Recent guidelines from the UK-based National Institute for Health and Care Excellence have suggested that patients with persistent respiratory symptoms should have a follow-up chest X-ray at 12 weeks. 5 There appear to be no recommendations about the use of corticosteroids in discharged COVID-19 patients.

This case report suggests that in patients who have required ICU admission, a chest X-ray 1-2 months after discharge may identify patients with a phenotype consistent with OP. Importantly, appropriate follow-up therapy with corticosteroids may potentially benefit such patients.

Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Organizing pneumonia of COVID-19: time-dependent evolution and outcome in CT findings

Severe organising pneumonia following COVID-19

COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19